Medicines: Oncology Portfolio and Pipeline
Home / Our therapy areas / Oncology / Medicines: Oncology Portfolio and Pipeline
在澳门葡京网赌游戏，澳门葡京赌博游戏的目标是通过澳门葡京赌博游戏的产品组合，澳门葡京赌博游戏的产品线和澳门葡京赌博游戏的员工来彻底改变癌症治疗. 无论科学把澳门葡京赌博游戏带到哪里，澳门葡京赌博游戏都追随它，追求最好的药物. Through this relentless quest for innovation, 澳门葡京赌博游戏已经创建了行业中最多样化的产品组合和管道之一，包括旨在优先杀死癌细胞的分子和模式, at every stage of disease.
Key disease areas
澳门葡京赌博游戏正在努力使全世界每天数百万癌症患者的治愈成为现实. 澳门葡京赌博游戏的重点是一些最恶劣和最难治疗的癌症，包括胰腺癌, certain blood cancers, and cancers within breast, lung, ovarian, and prostate. By understanding the complexities of these cancer types, we can truly achieve life-changing benefits for patients.
We are balancing our focus on our industry-leading pipeline with the active life-cycle management of our existing medicines; expanding indications and exploring novel treatment combinations, to deliver to those patients with the greatest unmet need. 在澳门葡京赌博游戏所做的每一件事上——从澳门葡京赌博游戏提供的治疗方案到这些治疗可能产生的日常影响——患者总是放在第一位的.
Explore our key disease areas
Our scientific platforms
At AstraZeneca, 澳门葡京赌博游戏在六个科学平台上的进步帮助改善了患者的治疗效果. Further developments in epigenetics and across cell, gene and combination therapy hold the promise of new possibilities.
Tumour Drivers and Resistance (TDR)
靶向基因突变和耐药机制，使癌细胞逃避治疗, survive, and proliferate
Antibody Drug Conjugates (ADC)
通过与靶向抗体相连的连接体将高效的抗癌剂直接输送到癌细胞中
Epigenetics
识别表观遗传变化(基因组如何表达)并部署针对癌细胞关键过程的抑制剂
Our Oncology medicines
澳门葡京网赌游戏的药品在个别国家获得了特定用途的批准, 澳门葡京赌博游戏提供给病人的信息受当地法规的约束. In some countries, 医疗保健专业人员和患者可以访问当地的澳门葡京网赌游戏网站，了解更多澳门葡京网赌游戏药物的信息. However, 请注意，在一些国家，澳门葡京赌博游戏不允许提供太多, or sometimes any, information on our prescription medicines, so you should only obtain information from trustworthy sources, and always ask a healthcare professional for advice about medicines.
Calquence
acalabrutinib
Enhertu
trastuzumab deruxtecan
Faslodex
fulvestrant
Imfinzi
durvalumab
Imjudo
tremelimumab
Iressa
gefitinib
Lynparza
olaparib
Orpathys
savolitinib
Truqap
capivasertib
Tagrisso
osimertinib
Zoladex
goserelin acetate implant
Our Oncology pipeline
在澳门葡京网赌游戏，澳门葡京赌博游戏行业领先的产品线包括处于临床开发各个阶段的研究性治疗-从批准的药物到临床试验的早期分子.
第三阶段/LCM项目:指在第二/第三阶段至关重要或已提交监管批准的资产，可能包括在一个或多个主要市场推出的资产(在所有适用的主要市场推出时移除).
Oncology (as of 25 June 2024)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
